Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 18/20 | 0.36 |
| ▸ | FLT3 | P36888 | 5/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114403 | 1.00 | TSHR (0.41) | TSHRSYKFLT3AURKBPDE4A | |
| SCHEMBL8312105 | 1.00 | TSHR (0.41) | TSHRSYKFLT3AURKBPDE4A | |
| SCHEMBL14671531 | 0.82 | — | — | |
| SCHEMBL6155366 | 0.82 | — | — | |
| SCHEMBL14749811 | 0.82 | — | — | |
| SCHEMBL523097 | 0.79 | TSHR (0.39) | TSHRSYKFLT3AURKBPDE4A | |
| SCHEMBL523098 | 0.79 | TSHR (0.39) | TSHRSYKFLT3AURKBPDE4A | |
| SCHEMBL9506103 | 0.79 | TSHR (0.39) | TSHRSYKFLT3AURKB | |
| SCHEMBL24457289 | 0.78 | — | — | |
| SCHEMBL524080 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| WO-2004054566-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | TSHR 2059/4885SYK 1/4885FLT3 15/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | TSHR 2467/4885SYK 3748/4885FLT3 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.